Compare Inovio Pharmaceuticals Inc (INO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs NetEase Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while NetEase Inc trades at $124.25 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 678.2× Inovio Pharmaceuticals Inc's market cap, and NetEase Inc pays a 2.45% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and NetEase Inc for 73 Days on average.
| INO | NTES | |
|---|---|---|
Market Cap | $112.19M | $76.09B |
Volume | 3,201,278 | 486,447 |
Sector | Health | Technology |
52-Week High | $2.65 | $152.85 |
52-Week Low | $0.66 | $109.26 |
Typical Hold Time | 43 Days | 73 Days |
Enterprise Value | $83.51M | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
NTES trades at $124.20, up 2.98% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 revenue growth of 8% year-over-year to $4.4 billion, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights focus on gaming performance and AI investments.
Outlook remains positive with an 81.82% analyst buy rating and a $168.00 consensus price target, implying significant upside. Risks include earnings volatility and competitive pressures in the gaming sector. The stock presents a value opportunity given its reasonable P/E of 15.92 and strong balance sheet with $137.58 billion in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
